BioLight Life Sciences Ltd
BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions. The company's ophthalmic product offering and pipeline of product candidates include DiagnosTear's TeaRx technology, a diagnostic platform for diagnosis of disease in the frontal areas of the eye through examination… Read more
BioLight Life Sciences Ltd (BOLT) - Total Liabilities
Latest total liabilities as of June 2025: ILA3.08 Million ILA
Based on the latest financial reports, BioLight Life Sciences Ltd (BOLT) has total liabilities worth ILA3.08 Million ILA as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BioLight Life Sciences Ltd - Total Liabilities Trend (2005–2024)
This chart illustrates how BioLight Life Sciences Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
BioLight Life Sciences Ltd Competitors by Total Liabilities
The table below lists competitors of BioLight Life Sciences Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Pharol SGPS S.A
PINK:PHRZF
|
USA | $2.04 Million |
|
Pacific Software Inc
PINK:PFSF
|
USA | $480.28K |
|
ANTA SPORTS PRODUCT (AS7.SG)
STU:AS7
|
Germany | €36.22 Billion |
|
CITIZEN HOLDINGS - Dusseldorf Stock Exchang
DU:CTZ
|
Germany | €159.31 Billion |
|
TonnerOne World Holdings Inc
PINK:TONR
|
USA | $1.98 Million |
Liability Composition Analysis (2005–2024)
This chart breaks down BioLight Life Sciences Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioLight Life Sciences Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioLight Life Sciences Ltd (2005–2024)
The table below shows the annual total liabilities of BioLight Life Sciences Ltd from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ILA3.38 Million | +7.27% |
| 2023-12-31 | ILA3.15 Million | -5.06% |
| 2022-12-31 | ILA3.32 Million | +20.52% |
| 2021-12-31 | ILA2.75 Million | -41.68% |
| 2020-12-31 | ILA4.72 Million | -30.60% |
| 2019-12-31 | ILA6.80 Million | -45.51% |
| 2018-12-31 | ILA12.49 Million | -25.38% |
| 2017-12-31 | ILA16.73 Million | -11.48% |
| 2016-12-31 | ILA18.90 Million | +16.61% |
| 2015-12-31 | ILA16.21 Million | +10.30% |
| 2014-12-31 | ILA14.70 Million | +20.23% |
| 2013-12-31 | ILA12.22 Million | +168.46% |
| 2012-12-31 | ILA4.55 Million | -25.18% |
| 2011-12-31 | ILA6.08 Million | -17.96% |
| 2010-12-31 | ILA7.42 Million | -19.22% |
| 2009-12-31 | ILA9.18 Million | -77.13% |
| 2006-12-31 | ILA40.15 Million | +1393.27% |
| 2005-12-31 | ILA2.69 Million | -- |